Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
British biotech is often a disregarded backwater in life sciences, but today a host of good news has shone the spotlight back onto its potential.
AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.
Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.
With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech, Phathom.
The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta 9-ING-41.
AZ nets exec to lead breast cancer R&D; Teva stars in price-fix plot, but attorneys general say others "willingly" joined; EUSA Pharma nabs new…
Roche subsidiary Genentech put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune diseases.
Immune molecules from sea lampreys could inspire new treatments for brain tumors, trauma and neurodegenerative diseases.
In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million.
In our EuroBiotech roundup this week, uniQure posts gene therapy data, Modus’ sickle cell trial fails and TreeFrog raises cash for cell therapy R&D.